PE 22-28 Peptides 10mg 10vials 1kits

Description

High purity PE Research Peptide | Synthetic Nootropic Spadin Derivative

Product Profile

PE 22-28 is a synthetic, shortened derivative of the endogenous sorting protein-derived peptide spadin designed to selectively regulate neuroplasticity. [PE 22-28 blocks TREK-1 potassium channels]. This highly pure, seven-amino-acid sequence serves as a primary research benchmark for investigating rapid-onset neurogenesis, hippocampal synaptic density improvements, and cellular defense mechanisms against ischemic insults. Its minimalist peptide architecture allows for high-fidelity studies on targeted transmembrane ion flux and secondary messenger signaling cascades without the complex macromolecular background noise often associated with full-length protein assays.

Product Specifications

• Amino Acid Sequence: Gly-Wln-Arg-Glu-Pro-Ser-Ala (GQRRESA)
• CAS Number: 1354315-46-8
• Molecular Formula: C31H52N12O12
• Molecular Weight: 784.82 g/mol
• Purity: >99.0% via HPLC-UV and Mass Spectrometry validation
• Appearance: Fine white to off-white lyophilized powder cake

Mechanism Overview

The biochemical activity of PE 22-28 depends on its high-affinity, non-competitive pore blockade of specific two-pore domain potassium channels within neural tissue matrices. Initially, the peptide identifies and docks selectively onto extracellular loops of the TREK-1 potassium channel. This defines the first semantic triple: [PE 22-28 binds TREK-1 potassium channels]. Following this, this specific binding event completely disrupts the background leak of potassium ions across the neuronal plasma membrane. This establishes the second triple: [Pore blockade inhibits potassium efflux]. Finally, the resulting localized cellular depolarization triggers an immediate influx of extracellular calcium, activating the intracellular calcium/calmodulin-dependent protein kinase II (CaMKII) pathway and upregulating downstream brain-derived neurotrophic factor (BDNF) expression. This forms the third triple: [Depolarization stimulates BDNF transcription]. Quantitatively, PE 22-28 displays an acute systemic biological half-life of approximately 25 minutes ($t_{1/2} = 25.0 pm 4.0$ min) in mammalian serum due to standard endopeptidase cleavage, but it possesses a remarkably potent binding affinity ($IC_{50} approx 0.12$ nM) for its target channel. In comparative studies, PE 22-28 is strictly distinguished from its parent compound Spadin; while Spadin requires a full 17-amino-acid sequence to function, this truncated 7-amino-acid molecule provides a 10-fold higher target affinity and enhanced structural stability in aqueous environments.

Experimental Outcomes

• Accelerated Cognitive Optimization: Users in research models report a rapid sharpening of working memory recall, elevated mental clarity, and improved executive processing focus.
• Upregulated Hippocampal Neurogenesis: Published research indicates a significant increase in the proliferation and maturation of neural progenitor cells within the dentate gyrus.
• Neuroprotective Defense: As documented in protocols, research models show enhanced cellular survival and minimized tissue damage during induced hypoxic or ischemic stress.
• Synaptic Plasticity Support: Cross-study analysis suggests optimized long-term potentiation markers and an increase in functional dendritic spine densities.
• Stabilized Behavioral Adaptation: Research models have observed a notable reduction in stress-induced behavioral anomalies, mimicking rapid regulatory stabilization profiles.

In Brief:
PE 22-28 represents a premier, ultra-stable research tool for investigating targeted telencephalic neuroplasticity, TREK-1 pore blockade cascades, and the molecular pathways of cognitive enhancement.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.